RE:RE:Questions for BOD/Management AGM submitted Benedict16th wrote: Longterm if GBT does not have great new upcoming drugs coming out of their pipeline GUD is toasted and GUD MNGT has made a financial mortal mistake. It may take LATAM over a decade if, to come out of the damage caused by Covid-19. So the fundamental question is.
What drugs GBT has in the pipeline and timeline. If GUD MNGT in the AGM omits and does not voluntarily offer detailed information on this topic you what the answers is. They F k ed up but will they never admit and they will go on with bs narratives changes of of the past. Let’s hope I am 100% . What they not say is what wories me.
OVERVIEW OF ACTIVITIES
The state of affairs of the Company at the closing of the financial year is adequately presented in the balance sheet and the profit and loss account, published herewith. With reference to the Group, our product development pipeline is divided into two business models: (1) partnership product development, which is focused on building relationships to license and commercialize innovative products that are new to Latin America, and (2) internal product development, which is focused on studying, designing, formulating and manufacturing branded generic (BGx) products, which are the bioequivalents of innovative products without patent protection. GBT´s commercial stage portfolio includes: (i) Launches (1 to 5-year-old products) are products launched recently and can be divided into key launches from innovative licensed products and launches from BGx line; (ii) Peak year products, which are approximately 5 years after launch, that already reached peak sales. It´s a mix of licensed and BGx products; (iii) Mature products from 10 years or over after launch, and usually already lost exclusivity and may start do decline over the years. It´s also a mix of licensed and BGx. Proprietary specialty products (BGx) are developed and manufactured in Argentina through four proprietary plants.
Six main products from the base portfolio (all stages, excluding only key/innovative launches) represented approximately 55% of total net revenues in 2019.
They are comprised by AMBISOME®, ABRAXANE®, SALOFALK®, LADEVINA®, HALAVEN® and VIDAZA®. Key launches are the main licensed products launched in the past five years. Usually, these products are still in the ramp up phase to reach peak market share. LENVIMA®, ABRAXANE® and HALAVEN® are contributing with sales in Brazil and ABRAXANE®/ABRAXUS® in Mexico as well. ABRAXANE®, HALAVEN® and LENVIMA® are already part of our top 10 products. GBT is working on the promotion and ramp up of these products and additional indications and/or registration in new countries for several of them. Recently launched products increased quarter to quarter, showing solid performance of new products and very good launch execution. The growth is related to the addition of new products since last year, such as EPCLUSA®. CRESEMBA® was also launched during the third quarter 2019 and sales have just started. https://s3.amazonaws.com/mz-filemanager/f78739c6-0e47-4145-8a2e-947b5835a922/718d5cf5-4649-463e-afe0-a03529a812bf_gbio_management%20proposal_eng_v5.pdf